iiinova — where your digital self keeps evolving

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 07/10/2026

Progress in precision #oncology depends on shared resources. @eaonc.bsky.social researchers are partnering with Caris Life Sciences to profile paired primary and recurrent breast tumors from two landmark trials, TAILORx and RxPONDER. During #BreastCancerAwareness learn more: bit.ly/ea1241-blog

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 06/10/2026

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 05/10/2026

EA1241, led by Dr. Joseph Sparano, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: bit.ly/EA1241

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 01/10/2026

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. bit.ly/ea8231-study

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 29/09/2026

The #BreastCancer study EA1242/RxFINE-Low is testing whether hormone therapy plus ribociclib, without chemotherapy, is as effective as standard treatment that includes chemotherapy. Learn more: bit.ly/ea1242-study

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 29/09/2026

#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

011

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 28/09/2026

#ClinicalTrial EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: bit.ly/EA7211

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 24/09/2026

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced urothelial cancer. The trial aims to improve treatment options & guide further research. ➡️ bit.ly/ea8231-study

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/09/2026

Do you have #BreastCancer that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: bit.ly/ea1242-study

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/09/2026

Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: bit.ly/ea5221-achieve

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 21/09/2026

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona aims to find out. More: bit.ly/EA7211 cc: European Organisation for Research and Treatment of Cancer

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 17/09/2026

Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new treatment approach for pts with treatment-refractory, locally-advanced or metastatic urothelial cancer. More information here: bit.ly/ea8231-study

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 15/09/2026

Clinical trial EA1242/RxFINE-Low, led by Dr. Nancy Chan of Perlmutter Cancer Center at NYU Langone Health, is testing whether hormone therapy plus ribociclib is as effective as chemotherapy followed by hormone therapy plus ribociclib in patients with #BreastCancer. More: bit.ly/ea1242-study

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 15/09/2026

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 14/09/2026

In #ClinicalTrial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal #sarcoma. More info: bit.ly/EA7211

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 05/05/2026

The #EAOnc Spring 2026 Group Meeting officially begins today! Looking forward to seeing you in Baltimore. Check in at the registration desk on the 4th floor before heading to your first session. 🩺🩻📈

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 01/05/2026

#FindingsFriday: Don’t miss the newest round-up of recently published findings from @eaonc.bsky.social #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/4ed3xb6

010

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 11/03/2026

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 20/02/2026

Trial Activation: EA6232, led by Dr. John Kirkwood of UPMC, is a phase II double-blind trial of sulforaphane for therapeutic prevention of #Melanoma in patients with multiple atypical nevi and a prior history of melanoma. Learn more: bit.ly/EA6232

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 12/02/2026

We’re headed back to Baltimore! The ECOG-ACRIN Spring 2026 Group Meeting will be held May 5–7, 2026 (Tues–Thurs, note the shift from Wed–Fri). Join us in Baltimore for plenary sessions, networking, and collaboration. Stay tuned for registration details. #EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 04/02/2026

On #WorldCancerDay, we thank the patients, advocates, clinicians, and research teams who make ECOG-ACRIN trials possible. Your participation drives discovery and delivers hope. #CancerCare #UnitedByUnique

010

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 26/01/2026

Fellows: Apply by 2/19 for the 2026 Paul Carbone, MD Fellowship Award, a research grant for senior oncology or hematology fellows that aims to develop & promote excellence in #clinicaltrials. Learn more: bit.ly/ea-carbone #cancerresearch

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 26/01/2026

EA1241, led by Dr. Joseph Sparano of The Mount Sinai Hospital, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: bit.ly/EA1241

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 21/01/2026

The nomination period is now open for the 2026 @eaonc.bsky.social Young Investigator Award! 🩺 This honor recognizes the scientific achievements of early-career investigators. Learn more & nominate a colleague by 2/19: bit.ly/ea-yia #mentorship #CancerResearch #ClinicalTrials

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 16/01/2026

EA is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below. 📅Feb 4 | 4 PM ET 🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD 🔗https://bit.ly/EA1241webinar

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 17/11/2025

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 29/10/2025

The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website. Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 23/10/2025

Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/10/2025

Thank you to the exceptional presenters and panelists who helped make the Fall 2025 Comis #TranslationalScience Symposium a success: Drs. Jon Steingrimsson, @rhubbbstat.bsky.social, Paul Catalano, Walter Witschey, @jordanberlin5.bsky.social, & Mary Lou Smith!

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/10/2025

Group Co-Chair Dr. Mitch Schnall of @pennmedicine.bsky.social kicks off the Fall 2025 Robert L. Comis Translational Science Symposium, focused on #AI, #RealWorldData, and alternative approaches to phase 2 and 3 therapeutic questions. #EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/10/2025

The Robert L. Comis, MD Translational Science Symposium on Approaches Using #AI and Other Electronic Methods in #ClinicalTrials is underway. Join us in Salon E, 5th Floor! #EAOnc #CancerResearch

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/10/2025

Congratulations to the Fall 2025 Edith Peterson Mitchell, MD Travel Scholars! #CancerResearch #ClinicalTrials #EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/10/2025

Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium! 🩻🩺📈#EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/10/2025

The #EAOnc Fall 2025 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺🩻📈

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 01/10/2025

You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm

010

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 30/09/2025

We congratulate Dr. Anthony Letai on his appointment as NCI Director. His deep scientific expertise & reputation as a collaborative leader make him an excellent choice to drive progress against #cancer. We look forward to working with him! #CancerResearch #ClinicalTrials

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 24/09/2025

Today is #WorldCancerResearchDay! Catch up on the latest @eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 18/09/2025

Today is the 2025 Rally for Medical Research! #RallyForNIH unites patients, survivors, researchers & advocates urging Congress to make National Institutes of Health funding a national priority. Join us in calling for sustained, robust NIH support. Important info➡️ rallyformedicalresearch.org

010

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 10/09/2025

ICYMI: Check out our round-up of recently published @eaonc.bsky.social research results. More here ➡️ bit.ly/aug25research #EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 10/09/2025

September is #ProstateCancerAwarenessMonth 💙. This month, we’re spotlighting EA8191/INDICATE, a #ClinicalTrial treating #ProstateCancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging. More here: bit.ly/indicate-trial

010

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 03/09/2025

In our August newsletter, the co-chairs spotlight an open letter to Congress from the National Clinical Trials Network Cooperative Group Chairs, detailing its significant contributions to patient welfare. Read their editorial and the full letter here: bit.ly/41x0VO5 #CancerResearch #ClinicalTrials

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 27/08/2025

The EA3211 clinical study is testing a potential new treatment for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: bit.ly/ea3211-study #hncsm

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 21/08/2025

Submit an Abstract for the 2025 Young Investigator Symposium by Thursday, 9/11! 🩻 We are now accepting research abstracts from early-career investigators interested in presenting your research as part of the upcoming Fall 2025 Group Meeting. More: bit.ly/yis-fall25 #EAOnc

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 21/08/2025

Trial Activation: EA2234/STOPGAP II, led by Dr. Maheswari Senthil of UCI Health, is a randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis. More: bit.ly/ea2234-stopg... #StomachCancer

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 12/08/2025

Trial Activation: EAA241, led by Dr. Amany Keruakous of @wellstarhealth.bsky.social, is a randomized phase II trial comparing daratumumab-bortezomib-dexamethasone vs cyclophosphamide-bortezomib dexamethasone in newly diagnosed #MultipleMyeloma. For more info: bit.ly/EAA241

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 01/08/2025

#FindingsFriday: Did you know we publish patient-friendly, 1-2 page summaries of the results of many of our #ClinicalTrials? View them here: bit.ly/trial-summar... #CancerResearch #ClinicalTrials

000

ECOG-ACRIN Cancer Research Group @eaonc.bsky.social · 22/07/2025

Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: bit.ly/EA4231 #lymsm

000